Impact of Body Mass Index on Progression of IgA Nephropathy Among Japanese Patients

Journal of Clinical Laboratory Analysis

Volumn 29, Issue 5, 2015, Pages 353-360

  Shimamoto, Mamiko ^a   Ohsawa, Isao ^a   Suzuki, Hiyori ^a   Hisada, Atsuko ^a   Nagamachi, Seiji ^a   Honda, Daisuke ^a   Inoshita, Hiroyuki ^a   Shimizu, Yoshio ^a   Horikoshi, Satoshi ^a   Tomino, Yasuhiko ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Body mass index; IgA nephropathy; Japanese; Metabolic syndrome; Obesity

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHYLPREDNISOLONE; PREDNISOLONE; TRIACYLGLYCEROL; URIC ACID;

ADULT; AGE DISTRIBUTION; AGED; ANALYTICAL PARAMETERS; ARTICLE; BODY MASS; CHILD; COMPLEMENT DISORDER; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEGREE OF RED BLOOD CELL; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE REDUCTION; DYSLIPIDEMIA; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN TISSUE; HYPERCOMPLEMENTEMIA; HYPERTENSION; HYPERURICEMIA; IMMUNOGLOBULIN A NEPHROPATHY; INCIDENCE; JAPANESE (PEOPLE); KIDNEY BIOPSY; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORPHOMETRICS; OBESITY; PATIENT CODING; PROTEIN URINE LEVEL; REMISSION; RISK FACTOR; SCHOOL CHILD; STEROID THERAPY; SYSTOLIC BLOOD PRESSURE; TONSILLECTOMY; TREATMENT DURATION; VERY ELDERLY; YOUNG ADULT; ADOLESCENT; GLOMERULONEPHRITIS, IGA; JAPAN; METABOLIC SYNDROME X; PATHOPHYSIOLOGY;

ADOLESCENT; ADULT; AGED; BODY MASS INDEX; CHILD; DISEASE PROGRESSION; FEMALE; GLOMERULONEPHRITIS, IGA; HUMANS; JAPAN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; YOUNG ADULT;

EID: 84941807241     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.21778     Document Type: Article

References (30)

1. Donadio JV, Grande JP. IgA nephropathy. N Engl J Med 2002;347:738-748.
2. Bolignano D, Zoccali C. Effects of weight loss on renal function in obese CKD patients: A systematic review. Nephrol Dial Transplant 2013;28(Suppl 4):iv82-iv98
3. Bonnet F, Deprele C, Sassolas A, et al. Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis. Am J Kidney Dis 2001;37:720-727.
4. World Health Organization. Obesity: Preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000;894:1-253.
5. Bei-Fan Z. Cooperative Meta-Analysis Group of Working Group on Obesity in China. Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults: Study on optimal cut-off points of body mass index and waist circumference in Chinese adults. Asia Pac J Clin Nutr 2002;11(Suppl 8):S685-S693.
6. Huxley R, James WP, Barzi F, et al. Obesity in Asia Collaboration. Ethnic comparisons of the cross-sectional relationships between measures of body size with diabetes and hypertension. Obes Rev 2008;9(Suppl 1):53-61.
7. Low S, Chin MC, Ma S, et al. Rationale for redefining obesity in Asians. Ann Acad Med Singapore 2009;38:66-69.
8. Matsuzaki K, Suzuki Y, Nakata J, et al. Nationwide survey on current treatments for IgA nephropathy in Japan. Clin Exp Nephrol 2013;17:827-833.
9. Matsuzawa Y. Metabolic syndrome-Definition and diagnostic criteria in Japan. J Atheroscler Thromb 2005;12:1-8.
10. Nakayama K, Ohsawa I, Maeda-Ohtani A, et al. Prediction of diagnosis of immunoglobulin A nephropathy prior to renal biopsy and correlation with urinary sediment findings and prognostic grading. J Clin Lab Anal 2008;22:114-118.
11. Tomino Y, Sakai H. Clinical guidelines for immunoglobulin A (IgA) nephropathy in Japan, second version. Clin Exp Nephrol 2003;7:93-97.
12. Pozzi C, Andrulli S, Del Vecchio L, et al. Corticosteroid effectiveness in IgA nephropathy: Long-term results of a randomized, controlled trial. F. J Am Soc Nephrol 2004;15:157-163.
13. Hotta O, Miyazaki M, Furuta T, et al. Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis 2001;38:736-743.
14. Ohsawa I, Kusaba G, Ishii M, et al. Extraglomerular C3 deposition and metabolic impacts in patients with IgA nephropathy. Nephrol Dial Transplant 2013;28:1856-1864.
15. Ohno I, Hosoya T, Gomi H, et al. Serum uric acid and renal prognosis in patients with IgA nephropathy. Nephron 2001;87:333-339.
16. Wakai K, Kawamura T, Endoh M, et al. A scoring system to predict renal outcome in IgA nephropathy: From a nationwide prospective study. Nephrol Dial Transplant 2006;21:2800-2808.
17. Syrjänen J, Mustonen J, Pasternack A. Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transplant 2000;15:34-42.
18. Wang L, Zhang Y, Chen S, et al. Association of metabolic syndrome and IgA nephropathy. J Clin Pathol 2010;63:697-701.
19. Tanaka M, Yamada S, Iwasaki Y, et al. Impact of obesity on IgA nephropathy: Comparative ultrastructural study between obese and non-obese patients. Nephron Clin Pract 2009;112:c71-c78.
20. Kambham N, Markowitz GS, Valeri AM, Lin J, D'Agati VD. Obesity-related glomerulopathy: An emerging epidemic. Kidney Int 2001; 59:1498-1509.
21. Suganami T, Ogawa Y. Adipose tissue macrophages: Their role in adipose tissue remodeling. J Leukoc Biol 2010;88:33-39.
22. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444:860-867.
23. Niculescu F, Rus H. The role of complement activation in atherosclerosis. Immunol Res 2004;30:73-80.
24. Ohsawa I, Inoshita H, Ishii M, et al. Metabolic impact on serum levels of complement component 3 in Japanese patients. J Clin Lab Anal 2010;24:113-118.
25. Suzuki H, Ohsawa I, Kodama F, et al. Fluctuation of serum C3 levels reflects disease activity and metabolic background in patients with IgA nephropathy. J Nephrol 2013;26:708-715.
26. Kim SJ, Koo HM, Lim BJ, et al. Decreased circulating C3 levels and mesangial C3 deposition predict renal outcome in patients with IgA nephropathy. PLoS One 2012;7:e40495.
27. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004; 363:157-163.
28. Snijder MB, van Dam RM, Visser M, Seidell JC. What aspects of body fat are particularly hazardous and how do we measure them? Int J Epidemiol 2006;35:83-92.
29. Silverwood RJ, Pierce M, Thomas C, et al.; National Survey of Health and Development Scientific and Data Collection Teams. Association between younger age when first overweight and increased risk for CKD. J Am Soc Nephrol 2013;24:813-21.
30. Othman M, Kawar B, El Nahas AM. Influence of obesity on progression of non-diabetic chronic kidney disease: A retrospective cohort study. Nephron Clin Pract 2009;113:c16-c23.